Because cytotoxicity is one of the major hurdles in the application of many transfection agents, an important feature of our cationic liposome is its low toxicity for cells at the concentrations ...

Please provide your email address to receive an email when new articles are posted on . The addition of intraperitoneal paclitaxel to systemic capecitabine and oxaliplatin appeared to benefit patients ...

A retrospective study compared progression-free and overall survival of hyperthermic intraperitoneal chemotherapy with conventional intraperitoneal chemotherapy in patients with ovarian cancer.

Cancers originating from organs in the peritoneal cavity (e.g., ovarian, pancreatic, colorectal, gastric and liver) account for approximately 250,000 new cancer cases annually in the USA. Peritoneal ...

Please provide your email address to receive an email when new articles are posted on . Adding hyperthermic intraperitoneal chemotherapy to cytoreductive surgery did not significantly prolong PFS or ...

HIPEC is a type of treatment for cancers that have spread within your abdomen. Doctors surgically remove the tumor and then pump heated chemotherapy drugs into your abdominal cavity. Hyperthermic ...

EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Intraperitoneal (IP) chemotherapy is a type of ovarian cancer treatment in which chemo drugs are directly pumped into your belly cavity (also called peritoneal cavity). When you get chemo this way, it ...

HIPEC surgery is a promising treatment option for patients with certain abdominal cancers. Surgical oncologist Erin Ward, MD, discusses which patients would be best candidates for HIPEC, explains why ...

We undertook an exploratory cross-trial analysis (Figure 1) comparing intraperitoneal cisplatin plus paclitaxel in the patients in the study by Armstrong et al. with intravenous carboplatin plus ...